

Neos Therapeutics, Inc.
 Form 3
 July 22, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>Â Presidio Partners 2007, L.P.</p> <p>(Last) (First) (Middle)</p> <p>ONE LETTERMAN DRIVE,Â BUILDING C, SUITE CM500</p> <p>(Street)</p> <p>SAN FRANCISCO,Â CAÂ 94129</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>07/22/2015</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>Neos Therapeutics, Inc. [NEOS]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p>___ Director <input checked="" type="checkbox"/> 10% Owner ___ Officer ___ Other (give title below) (specify below)</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p>___ Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person</p>
--	---	--	--	---	---

Table I - Non-Derivative Securities Beneficially Owned

<p>1. Title of Security (Instr. 4)</p>	<p>2. Amount of Securities Beneficially Owned (Instr. 4)</p>	<p>3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</p>	<p>4. Nature of Indirect Beneficial Ownership (Instr. 5)</p>
--	--	--	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<p>1. Title of Derivative Security (Instr. 4)</p>	<p>2. Date Exercisable and Expiration Date (Month/Day/Year)</p> <p>Date Exercisable Expiration Date</p>	<p>3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)</p> <p>Title Amount or Number of</p>	<p>4. Conversion or Exercise Price of Derivative Security</p>	<p>5. Ownership Form of Derivative Security: Direct (D)</p>	<p>6. Nature of Indirect Beneficial Ownership (Instr. 5)</p>
---	--	--	---	--	--

Edgar Filing: Neos Therapeutics, Inc. - Form 3

				Shares		or Indirect (1) (Instr. 5)	
Series B Redeemable Preferred Stock, \$0.001 par value	Â (1)	Â (1)	Common Stock	406,250	\$ (1)	D	Â
Series C Redeemable Preferred Stock, \$0.001 par value	Â (1)	Â (1)	Common Stock	677,622	\$ (1)	D	Â
Preferred Stock Warrant (Right to Buy)	Â (2)	01/30/2018	Series C Convertible Preferred Stock	390,000 (2)	\$ 5 (2)	D	Â
Series B Redeemable Preferred Stock, \$0.001 par value	Â (1)	Â (1)	Common Stock	10,416	\$ (1)	I	By: Presidio Partners 2007 (Parallel), L.P.
Series C Redeemable Preferred Stock, \$0.001 par value	Â (1)	Â (1)	Common Stock	17,374	\$ (1)	I	By: Presidio Partners 2007 (Parallel), L.P.
Preferred Stock Warrant (Right to Buy)	Â (2)	01/30/2018	Series C Convertible Preferred Stock	10,000 (2)	\$ 5 (2)	I	By: Presidio Partners 2007 (Parallel), L.P.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Presidio Partners 2007, L.P. ONE LETTERMAN DRIVE BUILDING C, SUITE CM500 SAN FRANCISCO, CA 94129	Â	Â X	Â	Â
Presidio Partners 2007 (Parallel), L.P. ONE LETTERMAN DRIVE BUILDING C, SUITE CM500 SAN FRANCISCO, CA 94129	Â	Â X	Â	Â
Presidio Partners 2007 GP, L.P. ONE LETTERMAN DRIVE BUILDING C, SUITE CM500 SAN FRANCISCO, CA 94129	Â	Â X	Â	Â
Presidio Partners 2007 GP, LLC ONE LETTERMAN DRIVE BUILDING C, SUITE CM500 SAN FRANCISCO, CA 94129	Â	Â X	Â	Â

Watson James F
 ONE LETTERMAN DRIVE
 BUILDING C, SUITE CM500
 SAN FRANCISCO, CA 94129

Sohail Faysal A.
 ONE LETTERMAN DRIVE
 BUILDING C, SUITE CM500
 SAN FRANCISCO, CA 94129

Collier David J
 ONE LETTERMAN DRIVE
 BUILDING C, SUITE CM500
 SAN FRANCISCO, CA 94129

Signatures

PRESIDIO PARTNERS 2007, L.P. By: Presidio Partners 2007 GP, L.P., its General Partner By: Presidio Partners 2007 GP LLC, its General Partner /s/ David J. Collier, Manager _____ **Signature of Reporting Person	07/22/2015 Date
Presidio Partners 2007 (Parallel), L.P., By: /s/ David J. Collier, Manager _____ **Signature of Reporting Person	07/22/2015 Date
Presidio Partners 2007 GP, L.P. /s/ David J. Collier, Manager _____ **Signature of Reporting Person	07/22/2015 Date
Presidio Partners 2007 GP, LLC /s/ David J. Collier, Manager _____ **Signature of Reporting Person	07/22/2015 Date
/s/ James F. Watson _____ **Signature of Reporting Person	07/22/2015 Date
/s/ Faysal A. Sohail _____ **Signature of Reporting Person	07/22/2015 Date
/s/ David J. Collier _____ **Signature of Reporting Person	07/22/2015 Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each share of the issuer's Series B Preferred Stock and Series C Preferred Stock will be automatically converted on a 2.4 for 1 basis into common stock immediately prior to the closing of the issuer's initial public offering and has no expiration.
 The warrant is exercisable at the earlier of (i) the holder's election for the number of shares of Series C preferred stock (a) shown in column 3 at a price of \$5.00 per share of Series C preferred stock or (b) such number of shares issuable pursuant to a cashless net exercise provision pursuant to which the holder surrenders the warrant and receives a net number of shares of Series C preferred stock based on the fair market value of such stock at the time of exercise, after deducting the aggregate exercise price (the "Cashless Exercise Provision"); and (ii) immediately prior to the closing of the Issuer's initial public offering pursuant to the Cashless Exercise Provision.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.